We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma.
- Authors
Sung, K. W.; Lee, S. H.; Yoo, K. H.; Jung, H. L.; Cho, E. J.; Koo, H. H.; Lee, S. K.; Kim, J.; Lim, D. H.; Suh, Y. L.; Kim, D. W.
- Abstract
From June 1997 to August 2005, 52 consecutive newly diagnosed stage 4 neuroblastoma patients over 1 year of age were assigned to receive tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) as consolidation therapy. Fifty of the 52 patients underwent a first HDCT/ASCR and 44 patients underwent a second HDCT/ASCR. Eight patients (15.4%) died from treatment-related toxicity (seven during the second HDCT/ASCR). Total body irradiation (TBI) in the first HDCT/ASCR and a shorter interval (<12 weeks) between the first and second HDCT/ASCR were associated with a higher rate of treatment-related death in the second HDCT/ASCR (P=0.032 and 0.095, respectively). The tumor relapsed or progressed in 11 patients, and 33 patients remained event free with a median follow-up of 53 months (range 19–117) from diagnosis. The 5-year event-free survival (EFS) (±95% confidence interval) for all 52 patients was 62.1±13.7%. The application of TBI and local radiotherapy, and a longer interval between the first and second HDCT/ASCR were independently associated with a better EFS (P=0.026, 0.007 and 0.020, respectively). However, further studies will be needed to decrease the toxic death rate in the second HDCT/ASCR while reducing the relapse rate.Bone Marrow Transplantation (2007) 40, 37–45; doi:10.1038/sj.bmt.1705691; published online 30 April 2007
- Subjects
DRUG therapy; ANTITUSSIVE agents; DRUG administration; DRUG prescribing; STEM cells; TUMORS in children
- Publication
Bone Marrow Transplantation, 2007, Vol 40, Issue 1, p37
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/sj.bmt.1705691